|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
26.31(B) |
Last
Volume: |
3,294,635 |
Avg
Vol: |
2,072,018 |
52
Week Range: |
$64 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 520 |
Guru Rank Value : 3.6 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
4,915 |
71,783 |
301,616 |
583,537 |
Total Sell Value |
$371,314 |
$9,377,154 |
$39,059,786 |
$70,857,495 |
Total People Sold |
5 |
8 |
14 |
16 |
Total Sell Transactions |
7 |
19 |
46 |
88 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dolan Matthew Vincent |
SVP Corporate Development |
|
2022-03-09 |
4 |
D |
$406.06 |
$655,782 |
D/D |
(1,615) |
8,820 |
|
- |
|
Selvaraj Shelly Ramasamy |
SVP Chief Information Officer |
|
2022-03-09 |
4 |
D |
$406.06 |
$757,296 |
D/D |
(1,865) |
13,820 |
|
- |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2022-03-09 |
4 |
D |
$406.06 |
$4,054,476 |
D/D |
(9,985) |
100,883 |
|
- |
|
Patterson Chad |
EVP, Global Marketing |
|
2022-03-09 |
4 |
D |
$406.06 |
$739,429 |
D/D |
(1,821) |
16,004 |
|
- |
|
Regan Barry J. |
EVP Global Operations |
|
2022-03-09 |
4 |
D |
$406.06 |
$268,403 |
D/D |
(661) |
17,451 |
|
- |
|
Abbey Donald |
EVP Quality Regulatory Affairs |
|
2022-03-09 |
4 |
D |
$406.06 |
$1,392,368 |
D/D |
(3,429) |
50,229 |
|
- |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2022-03-09 |
4 |
D |
$406.06 |
$1,392,368 |
D/D |
(3,429) |
35,925 |
|
- |
|
Sylvain Jereme M |
EVP, Chief Financial Officer |
|
2022-03-09 |
4 |
D |
$406.06 |
$792,217 |
D/D |
(1,951) |
18,008 |
|
- |
|
Balo Andrew K |
EVP, Global Medical Affairs |
|
2022-03-09 |
4 |
D |
$406.06 |
$1,392,774 |
D/D |
(3,430) |
15,615 |
|
- |
|
Leach Jacob Steven |
EVP Chief Technology Officer |
|
2022-03-08 |
4 |
A |
$0.00 |
$7 |
D/D |
6,741 |
79,019 |
|
- |
|
Flynn Paul R |
EVP Global Revenue |
|
2022-03-08 |
4 |
A |
$0.00 |
$5 |
D/D |
5,297 |
19,150 |
|
- |
|
Shrishrimal Sumi |
SVP Chief Risk Officer |
|
2022-03-08 |
4 |
A |
$0.00 |
$3 |
D/D |
2,889 |
15,146 |
|
- |
|
Stern Sadie |
EVP Chief Human Resources Off |
|
2022-03-08 |
4 |
A |
$0.00 |
$5 |
D/D |
5,297 |
18,758 |
|
- |
|
Dolan Matthew Vincent |
SVP Corporate Development |
|
2022-03-08 |
4 |
A |
$0.00 |
$3 |
D/D |
2,889 |
10,435 |
|
- |
|
Selvaraj Shelly Ramasamy |
SVP Chief Information Officer |
|
2022-03-08 |
4 |
A |
$0.00 |
$3 |
D/D |
2,889 |
15,685 |
|
- |
|
Sayer Kevin R |
Chairman, CEO & President |
|
2022-03-08 |
4 |
A |
$0.00 |
$16 |
D/D |
16,251 |
110,868 |
|
- |
|
Patterson Chad |
EVP, Global Marketing |
|
2022-03-08 |
4 |
A |
$0.00 |
$5 |
D/D |
5,297 |
17,825 |
|
- |
|
Regan Barry J. |
EVP Global Operations |
|
2022-03-08 |
4 |
A |
$0.00 |
$5 |
D/D |
4,984 |
18,112 |
|
- |
|
Abbey Donald |
EVP Quality Regulatory Affairs |
|
2022-03-08 |
4 |
A |
$0.00 |
$5 |
D/D |
4,984 |
53,658 |
|
- |
|
Pacelli Steven Robert |
Managing Dir., Dexcom Ventures |
|
2022-03-08 |
4 |
A |
$0.00 |
$5 |
D/D |
4,984 |
39,354 |
|
- |
|
Brown Micheal Jon |
EVP Chief Legal Officer |
|
2022-03-08 |
4 |
A |
$0.00 |
$12 |
D/D |
12,038 |
12,038 |
|
- |
|
Sylvain Jereme M |
EVP, Chief Financial Officer |
|
2022-03-08 |
4 |
A |
$0.00 |
$5 |
D/D |
5,297 |
19,959 |
|
- |
|
Balo Andrew K |
EVP, Global Medical Affairs |
|
2022-03-08 |
4 |
A |
$0.00 |
$5 |
D/D |
4,984 |
19,045 |
|
- |
|
Dolan Matthew Vincent |
*Officer |
|
2022-03-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,546 |
|
- |
|
Sylvain Jereme M |
EVP, Chief Financial Officer |
|
2022-03-04 |
4 |
AS |
$422.94 |
$253,764 |
D/D |
(600) |
14,662 |
|
- |
|
1713 Records found
|
|
Page 9 of 69 |
|
|